Please login to the form below

Not currently logged in
Email:
Password:

stomach cancer

This page shows the latest stomach cancer news and features for those working in and with pharma, biotech and healthcare.

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

such as stomach cancer. ... cancer, which was licensed in a deal worth up to $6.9bn by AstraZeneca in March.

Latest news

  • Vyriad inks immunotherapy alliance with Merck/Pfizer Vyriad inks immunotherapy alliance with Merck/Pfizer

    Oncolytic viruses are engineered to selectively replicate within and destroy cancer cells while simultaneously augmenting anti-tumour immunity, and are generally injected directly into tumour sites. ... cell lung cancer and also had a knockback in

  • Merck/Pfizer’s cancer immunotherapy latecomer hits a snag Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

    use into the much bigger non-small cell lung cancer (NSCLC) category are looking shaky after the failure of the JAVELIN Lung 200 study. ... It’s not the first setback for Bavencio, which failed a trial in third-line stomach cancer treatment last year,

  • Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

    Fails late-stage stomach cancer study. Already playing catch-up in the immuno-oncology market, Merck KGaA and Pfizer’s hopes for their PD-L1 inhibitor Bavencio just took a knock ... These include Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers

  • Mylan gets first biosimilar Herceptin OK from FDA Mylan gets first biosimilar Herceptin OK from FDA

    The biosimilar – developed by Mylan and Biocon and called Ogivri (trastuzumab-dkst) – has been approved by the FDA for HER2-positive breast or metastatic stomach cancer, the same indications as Herceptin ... This is especially important when it comes

  • Keytruda adds stomach cancer to growing list of US approvals Keytruda adds stomach cancer to growing list of US approvals

    an FDA green light for use of the drug in stomach cancer. ... The company notes that Keytruda is the first PD-1 inhibitor to be approved for stomach cancer in the US and will be used for patients who have disease progression despite

More from news
Approximately 4 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Country report: The healthcare market in China Country report: The healthcare market in China

    Leading public health issues include HIV/AIDS, cancer (stomach, lung, liver, cervical, breast) and heart diseases. ... Approximately 400, 000 patients are newly diagnosed with stomach cancer annually, with a rising prevalence in the number of younger

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    3. Coronary heart disease. 4. Lung cancer. 5. Stomach cancer. 6. ... The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs).  .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics